BCBS Kansas coverage for Ozempic (Kidney Disease (CKD))
Employer / Commercial Insurance
Covered (preferred drug)
What you need to qualify
A1C of 6.5% or higher
Lab results confirming eligibility
Qualification pathways
You can qualify through any one of these.
CKD with T2DM
All of:
Diagnosis of type 2 diabetes
A1C >= 6.5% confirmed by lab test or medical records
Patient has chronic kidney disease (CKD)
Requested agent will be used to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death
Patient will NOT use requested agent in combination with a DPP-4 containing agent
Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient age is within FDA labeling OR there is support for use outside labeled age range
Documentation to bring
Documentation of type 2 diabetes diagnosis
Lab test results or medical records confirming A1C >= 6.5%
Documentation of chronic kidney disease (CKD) diagnosis
Confirmation that requested agent will be used to reduce sustained eGFR decline, ESKD, or cardiovascular death
Confirmation that patient will not use with DPP-4 containing agent
Confirmation that patient will not use with another GLP-1 receptor agonist
Quantity limits
2 MG/3ML, 4 MG/3ML, 8 MG/3ML — 1 pen per 28 days
Approval and renewal
Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for Continuation requires prior preferred agent use within 90 days or prescriber attestation of risk if discontinued.
Not covered when
Combination with DPP-4 containing agents not permitted
Combination with another GLP-1 receptor agonist not permitted
FDA labeled contraindications to the requested agent
Personal or family history of MTC or MEN 2
Prior serious hypersensitivity reaction to semaglutide or product components
Policy note: CKD is a qualifying pathway under the diabetes PA criteria. The policy requires T2DM diagnosis AND A1C >= 6.5% in addition to CKD. Specific eGFR or UACR thresholds are not defined in this policy. No specific CKD staging requirements are listed.
Policy effective May 11, 2026 · verified June 2, 2026 · source: KS_GLP1_ProgSum.pdf
ACA Marketplace
Covered (preferred drug)
What you need to qualify
A1C of 6.5% or higher
Lab results confirming eligibility
Qualification pathways
You can qualify through any one of these.
CKD with T2DM
All of:
Diagnosis of type 2 diabetes
A1C >= 6.5% confirmed by lab test or medical records
Patient has chronic kidney disease (CKD)
Requested agent will be used to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death
Patient will NOT use requested agent in combination with a DPP-4 containing agent
Patient will NOT use requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient age is within FDA labeling OR there is support for use outside labeled age range
Documentation to bring
Documentation of type 2 diabetes diagnosis
Lab test results or medical records confirming A1C >= 6.5%
Documentation of chronic kidney disease (CKD) diagnosis
Confirmation that requested agent will be used to reduce sustained eGFR decline, ESKD, or cardiovascular death
Confirmation that patient will not use with DPP-4 containing agent
Confirmation that patient will not use with another GLP-1 receptor agonist
Quantity limits
2 MG/3ML, 4 MG/3ML, 8 MG/3ML — 1 pen per 28 days
Approval and renewal
Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for Continuation requires prior preferred agent use within 90 days or prescriber attestation of risk if discontinued.
Not covered when
Combination with DPP-4 containing agents not permitted
Combination with another GLP-1 receptor agonist not permitted
FDA labeled contraindications to the requested agent
Personal or family history of MTC or MEN 2
Prior serious hypersensitivity reaction to semaglutide or product components
Policy note: CKD is a qualifying pathway under the diabetes PA criteria. The policy requires T2DM diagnosis AND A1C >= 6.5% in addition to CKD. Specific eGFR or UACR thresholds are not defined in this policy. No specific CKD staging requirements are listed.
Policy effective May 11, 2026 · verified June 2, 2026 · source: KS_GLP1_ProgSum.pdf
